Filing Details

Accession Number:
0001493152-24-006178
Form Type:
13G Filing
Publication Date:
2024-02-12 19:00:00
Filed By:
Sb Investment Advisers (uk) Ltd
Company:
Vir Biotechnology Inc. (NASDAQ:VIR)
Filing Date:
2024-02-13
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
SVF Endurance (Cayman) Limited 0 16,684,041 0 16,684,041 16,684,041 12.4%
SoftBank Vision Fund (AIV M1) 0 16,684,041 0 16,684,041 16,684,041 12.4%
SB Investment Advisers (UK) Limited 0 16,684,041 0 16,684,041 16,684,041 12.4%
Filing

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Schedule 13G

(Rule 13d-102)

 

Information to be Included in Statements Filed Pursuant

to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

Pursuant to § 240.13d-2

 

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

(Amendment No. 2)*

 

Vir Biotechnology, Inc.

(Name of Issuer)

 

Common Stock

(Title of Class of Securities)

 

92764N102

(CUSIP Number)

 

December 31, 2023

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

CUSIP No. 92764N102 Schedule 13G Page 1 of 7

 

1

Names of Reporting Persons

 

SVF Endurance (Cayman) Limited

2 Check the Appropriate Box if a Member of a Group (a) ☐
    (b) ☐
3

SEC Use Only

 

4

Citizenship or Place of Organization

 

Cayman Islands

Number of Shares Beneficially Owned by Each Reporting Person With 5

Sole Voting Power

 

0

6

Shared Voting Power

 

16,684,041

7

Sole Dispositive Power

 

0

8

Shared Dispositive Power

 

16,684,041

9

Aggregate Amount Beneficially Owned by Each Reporting Person

 

16,684,041

10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares

Not Applicable
11 Percent of Class Represented by Amount in Row 9

12.4%
12 Type of Reporting Person

CO

 

 

 

 

CUSIP No. 92764N102 Schedule 13G Page 2 of 7

 

1

Names of Reporting Persons

 

SoftBank Vision Fund (AIV M1) L.P.

2 Check the Appropriate Box if a Member of a Group (a) ☐
    (b) ☐
3

SEC Use Only

 

4

Citizenship or Place of Organization

 

Delaware

Number of Shares

Beneficially Owned by Each Reporting Person With

5

Sole Voting Power

 

0

6

Shared Voting Power

 

16,684,041

7

Sole Dispositive Power

 

0

8

Shared Dispositive Power

 

16,684,041

9

Aggregate Amount Beneficially Owned by Each Reporting Person

 

16,684,041

10

Check if the Aggregate Amount in Row (9) Excludes Certain Shares

 

Not Applicable

11

Percent of Class Represented by Amount in Row 9

 

12.4%

12

Type of Reporting Person

 

PN

 

 

 

 

CUSIP No. 92764N102 Schedule 13G Page 3 of 7

 

1

Names of Reporting Persons

 

SB Investment Advisers (UK) Limited

2 Check the Appropriate Box if a Member of a Group (a) ☐
    (b) ☐
3

SEC Use Only

 

4

Citizenship or Place of Organization

 

England and Wales

Number of Shares Beneficially Owned by Each Reporting Person With 5

Sole Voting Power

 

0

6

Shared Voting Power

 

16,684,041

7

Sole Dispositive Power

 

0

8

Shared Dispositive Power

 

16,684,041

9

Aggregate Amount Beneficially Owned by Each Reporting Person

 

16,684,041

10

Check if the Aggregate Amount in Row (9) Excludes Certain Shares

 

Not Applicable

11

Percent of Class Represented by Amount in Row 9

 

12.4%

12

Type of Reporting Person

 

CO

 

 

 

 

CUSIP No. 92764N102 Schedule 13G Page 4 of 7

 

ITEM 1. (a) Name of Issuer:

 

Vir Biotechnology, Inc. (the “Issuer”).

 

  (b) Address of Issuer’s Principal Executive Offices:

 

1800 Owens Street, Suite 900, San Francisco, CA 94158

 

ITEM 2. (a) Name of Person Filing:

 

Each of the following is hereinafter individually referred to as a “Reporting Person” and collectively as the “Reporting Persons.” This statement is filed on behalf of:

 

SVF Endurance (Cayman) Limited

SoftBank Vision Fund (AIV M1) L.P. (“SVF”)

SB Investment Advisers (UK) Limited (“SBIA UK”)

 

  (b) Address or Principal Business Office:

 

The principal business address of SVF Endurance (Cayman) Limited is c/o Walkers Corporate Ltd., 190 Elgin Avenue, George Town, Grand Cayman KY1-9008, Cayman Islands. The principal business address of SVF is 251 Little Falls Drive Wilmington, DE 19808. The principal business address of SBIA UK is 69 Grosvenor Street, London, W1K 3JP, United Kingdom.

 

  (c) Citizenship of each Reporting Person is:

 

SVF Endurance (Cayman) Limited is organized under the laws of the Cayman Islands. SVF is organized under the laws of the State of Delaware. SBIA UK is organized under the laws of England and Wales.

 

  (d) Title of Class of Securities:

 

Common stock, par value $0.0001 per share (“Common Stock”).

 

  (e) CUSIP Number:

 

92764N102

 

ITEM 3.

 

Not applicable.

 

 

 

 

CUSIP No. 92764N102 Schedule 13G Page 5 of 7

 

ITEM 4. Ownership.

 

(a-c)

 

The ownership information presented below represents beneficial ownership of Common Stock of the Issuer as of December 31, 2023, based upon 134,521,285 shares of Common Stock outstanding as of October 27, 2023, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 3, 2023.

 

Reporting Person 

Amount

beneficially

owned

  

Percent

of class:

   Sole power to vote or to direct the vote:   Shared power to vote or to direct the vote:  

Sole power to dispose or to direct the disposition

of:

  

Shared

power to

dispose or

to direct

the

disposition

of:

 
SVF Endurance (Cayman) Limited   16,684,041    12.4%   0    16,684,041    0    16,684,041 
SoftBank Vision Fund (AIV M1) L.P.   16,684,041    12.4%   0    16,684,041    0    16,684,041 
SB Investment Advisers (UK) Limited   16,684,041    12.4%   0    16,684,041    0    16,684,041 

 

SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF is the sole owner of SVF Endurance (Cayman) Limited.

 

SBIA UK has been appointed as alternative investment fund manager (“AIFM”) of SVF. SBIA UK is authorized and regulated by the UK Financial Conduct Authority and is exclusively responsible for making all decisions related to the acquisition, structuring, financing and disposal of SVF’s investments. As a result of these relationships, each of the Reporting Persons may be deemed to share beneficial ownership of the securities reported herein.

 

ITEM 5. Ownership of Five Percent or Less of a Class.

 

Not applicable.

 

ITEM 6. Ownership of More than Five Percent on Behalf of Another Person.

 

Not applicable.

 

ITEM 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

 

Not applicable.

 

ITEM 8. Identification and Classification of Members of the Group.

 

Not applicable.

 

ITEM 9. Notice of Dissolution of Group.

 

Not applicable.

 

ITEM 10. Certification.

 

Not applicable.

 

 

 

 

CUSIP No. 92764N102 Schedule 13G Page 6 of 7

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date: February 13, 2024

 

  SVF Endurance (Cayman) Limited
   
  By: /s/ Karen Ellerbe
  Name: Karen Ellerbe
  Title: Director
   
  SoftBank Vision Fund (AIV M1) L.P.
   
  By: SB Investment Advisers (UK) Limited, its manager
   
  By: /s/ Amanda Sanchez-Barry
  Name: Amanda Sanchez-Barry
  Title: General Counsel
   
  SB Investment Advisers (UK) Limited
   
  By: /s/ Amanda Sanchez-Barry
  Name: Amanda Sanchez-Barry
  Title: General Counsel

 

 

 

 

CUSIP No. 92764N102 Schedule 13G Page 7 of 7

 

LIST OF EXHIBITS

 

Exhibit No.   Description
99   Joint Filing Agreement (previously filed).